tiprankstipranks
OKYO Pharma Advances in Ocular Treatment Trials
Company Announcements

OKYO Pharma Advances in Ocular Treatment Trials

OKYO Pharma Limited Sponsored ADR (OKYO) has released an update.

Pick the best stocks and maximize your portfolio:

OKYO Pharma Limited is set to present its promising trial results for OK-101, a treatment for dry eye disease, at the International Tear Film & Ocular Surface Society Conference in Venice. The company is also advancing its Phase 2 trial for treating Neuropathic Corneal Pain, a market with no current FDA-approved therapies. These developments highlight OKYO’s commitment to addressing challenging ocular conditions and expanding its presence in the multi-billion-dollar eye care market.

For further insights into OKYO stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskOKYO Pharma to Highlight Innovations at BTIG Conference
TipRanks Auto-Generated NewsdeskOKYO Pharma Begins Key Trial for Eye Pain Therapy
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App